Compass Therapeutics/$CMPX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Ticker
$CMPX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
35
ISIN
US20454B1044
Website
CMPX Metrics
BasicAdvanced
$365M
-
-$0.40
1.19
-
Price and volume
Market cap
$365M
Beta
1.19
52-week high
$4.08
52-week low
$0.82
Average daily volume
830K
Financial strength
Current ratio
8.332
Quick ratio
7.559
Long term debt to equity
5.687
Total debt to equity
5.786
Profitability
EBITDA (TTM)
-61.246
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-6,496.59%
Operating margin (TTM)
-7,273.06%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-26.41%
Return on equity (TTM)
-41.31%
Valuation
Price to revenue (TTM)
428.016
Price to book
3.31
Price to tangible book (TTM)
3.31
Price to free cash flow (TTM)
-8.223
Free cash flow yield (TTM)
-12.16%
Free cash flow per share (TTM)
-32.10%
Growth
Earnings per share change (TTM)
14.28%
3-year earnings per share growth (CAGR)
-28.33%
What the Analysts think about CMPX
Analyst ratings (Buy, Hold, Sell) for Compass Therapeutics stock.
Bulls say / Bears say
Compass Therapeutics' tovecimig (CTX-009) met the primary endpoint in a Phase 2/3 study for biliary tract cancer, achieving a 17.1% overall response rate compared to 5.3% for paclitaxel alone, indicating strong clinical efficacy. (stocktitan.net)
Analysts have shown optimism, with Raymond James Financial upgrading CMPX to an 'Outperform' rating and setting a $9.00 price target, suggesting significant upside potential. (marketbeat.com)
Compass Therapeutics has a robust pipeline, including CTX-471 and CTX-8371, with upcoming trials and readouts in 2025, potentially adding value to the company's portfolio. (wallstrank.com)
Leerink Partners downgraded CMPX from 'Outperform' to 'Market Perform' in November 2024, reducing the price target from $5.00 to $4.00, reflecting concerns about the company's performance. (defenseworld.net)
Millennium Management LLC significantly reduced its holdings in Compass Therapeutics by 80% during the fourth quarter, indicating potential lack of confidence from institutional investors. (marketbeat.com)
Despite positive trial results, the discontinuation of the CTX-471 + pembrolizumab trial due to safety concerns narrows the scope of Compass's pipeline, potentially impacting future growth. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CMPX Financial Performance
Revenues and expenses
CMPX Earnings Performance
Company profitability
CMPX News
AllArticlesVideos
Compass Therapeutics to Participate in Upcoming May Investor Events
GlobeNewsWire·2 months ago
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewsWire·2 months ago
2 Penny stocks to buy in May 2025
Finbold·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Compass Therapeutics stock?
Compass Therapeutics (CMPX) has a market cap of $365M as of July 08, 2025.
What is the P/E ratio for Compass Therapeutics stock?
The price to earnings (P/E) ratio for Compass Therapeutics (CMPX) stock is 0 as of July 08, 2025.
Does Compass Therapeutics stock pay dividends?
No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Compass Therapeutics dividend payment date?
Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Therapeutics?
Compass Therapeutics (CMPX) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.